Pfenex names Eef Schimmelpennink as CEO

3 August 2017

US clinical-stage biotech firm Pfenex (NYSE: PFNX) today announced the appointment of Evert (Eef) Schimmelpennink as chief executive, president, and secretary effective August 3, 2017.

Mr. Schimmelpennink was also appointed to serve as a Class III member of the board of directors effective August 3, 2017. Patrick Lucy, who held the post of interim CEO, president and secretary, will continue in his role as chief business officer.

Mr Schimmelpennink brings to Pfenex a broad base of biotechnology and pharmaceutical experience with strategic and functional expertise across corporate development, commercial operations, manufacturing and R&D. Prior to joining Pfenex, he served as CEO of Alvotech, a biosimilar development company, vice president Global Injectables at Pfizer and VP Global Generics of Hospira.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK